Acquisition brings Scaling of Pathology and Diagnostic Services

AI Technology developer Cyted has acquired Pathognomics Ltd, a provider of digital pathology and clinical diagnostic laboratory services. The addition of the UK-based company’s accredited laboratory environment and digital pathology technology will enable expansion of novel biomarkers and artificial intelligence (AI) technology at Cyted. The companies have already worked together on the launch of diagnostic services for the earlier detection of oesophageal cancer and will now look to scale their combined diagnostic reporting services and infrastructure.

All Pathognomics employees will now join the Cyted group, taking the Company’s total headcount from 15 to 23. Pathognomics’ Co-Founder and Laboratory Director Christopher Evagora will become Cyted’s Senior Director of Laboratory Operations, and Alec Hirst, Co-Founder and Project Director will become Cyted’s Senior Director of Business Technology. Cyted will remain headquartered in Cambridge whilst laboratory operations will continue in Huntingdon. To accommodate the expanding teams, the Company is increasing its laboratory and office space.

Marcel Gehrung, CEO, Cyted, said: “We are delighted to expand our team with the acquisition of Pathognomics. We have seen great synergy in our work and values through our partnership to launch and deliver our integrated diagnostic service. Merging the two companies is the next step in fulfilling our vision at Cyted, to change lives by enabling earlier disease detection and diagnosis.”